Pipeline Strengthens Leadership

Crinetics’ pipeline remains extensive, featuring atumelnant for congenital adrenal hyperplasia and ACTH‑dependent Cushing’s syndrome, as well as candidates targeting neuroendocrine tumors, Graves disease, polycystic kidney disease and GPCR‑targeted oncology indications. The European Commission approval of PALSONIFY is expected to strengthen the company’s growth prospects and solidify its global leadership in endocrinology.